Business

We are working on a drug discovery based on structural analysis using a Cryo-electron microscope (Cryo-EM).

What is a Cryo-EM?

 

 

Introduction of research achievements related to our Cryo-EM works
(including research achievements of our outside board members)

Member

Motoki Nakai
Chief Executive Officer
Osamu Nureki
Director
Yoshiyuki Kobayashi
VP / Chief Scientific Officer
Yuichi Matsubara
VP of Corporate & Business Development
Ayako Maita
Structural Biology Senior Researcher
Dan Sato
Structural Biology Senior Researcher
Katsumi Omagari
Structural Biology Senior Researcher
Yosuke Yamada
Scientific Development Senior Researcher
Naoyoshi Noguchi
Scientific Development Senior Researcher
Yuya Ogata
Scientific Development Senior Researcher
Akihiro Kawakita
Scientific Development Senior Researcher
Yoshiaki Kise
Structural Biology Senior Researcher
Hina Iden
Corporate

Advisor: Shunsuke Mori

Technical Advisor: Yuzuru Ito (Associate Professor Department of Biophysics and Biochemistry)

Company Profile

Company Name Curreio, Inc.
HQ Location Room 357, South Clinical Research Laboratory, Tokyo University, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan, 113-8485
Representative CEO Motoki Nakai
Establishment August 2019
Capital Approximately 380 million yen (including capital reserve)
Business Contents Drug discovery and R & D business based on structural analysis using Cryo-EM
Legal Advisor Anderson Mōri & Tomotsune
Shareholders Beyond Next Ventures, Ono Venture Investment, Asahi Kasei Pharma, GEMSEKI, Etc.

 

Access

Office/Lab

Room 357, South Clinical Research Laboratory, Tokyo University,
7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan, 113-8485

Currently, in order to strengthen the alert for COVID-19 at the University of Tokyo,
please call our staff when you arrive at the South Clinical Research Building.

Inquiry

We accept consultations and joint research on structure-based drug discovery (SBDD).

If you are interested, please contact us from the inquiry page.

MENU